Anne-Marie Duliege was named chief medical officer of the Pancreatic Cancer Action Network.
Homologous recombination deficiency tests are used routinely in the clinic to determine which patients get PARP inhibitors.
Anne-Marie Duliege named CMO of the Pancreatic Cancer Action Network
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
Homologous recombination deficiency tests are available from multiple vendors, and every day they are used to determine whether patients stand to benefit from PARP inhibitors.Â
Unquestionably, a child’s cancer diagnosis weighs heavily on the parents’ minds. But now, an analysis of nearly 30,000 U.S. families has quantified how often parents of children with cancer use mental health services.Â
Sen. Richard J. Durbin (D-IL) has asked Amgen to provide copies of the company’s communications with FDA related to the dosage of Lumakras (sotorasib), a KRAS inhibitor marketed under an accelerated approval for non-small cell lung cancer.
The healthcare sector’s necessary transition towards electronic health records (EHRs) has transformed patient care and operational efficiency.
Daniel M. Geynisman was named the editor-in-chief of JNCCN—Journal of the National Comprehensive Cancer Network.Â
